

REXAM

2012
Full year results

20 February 2013

Important notice

This presentation contains forward looking statements, which are based on the Rexam Board's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this presentation are based on past trends or activities and should not be taken as a representation that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the companies comprising the Rexam Group, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Group's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of raw material and other input costs; accounting for defined benefit or other pension schemes; and operating and financial restrictions as a result of financing arrangements.

No statement in this presentation is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Group. Each forward looking statement relates only as of the date of the particular statement. Except as required by the Listing Rules, the Disclosure and Transparency Rules, the Prospectus Rules, the London Stock Exchange or otherwise by law, the Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The information in this presentation does not constitute an offer to sell or an invitation to buy shares in Rexam PLC or an invitation or inducement to engage in any other investment activity.

REXAM

Stuart Chambers

Chairman

REXAM

David Robbie

Finance Director

Financial performance

£m	2012 Total	2012 Personal Care	2012 Continuing ¹	2011 Continuing ²	Reported change	Organic change ⁴
Sales	4,760	448	4,312	4,232	2%	4%
Operating profit ³	537	33	504	512	(2)%	1%
Total net finance cost ³	(96)	(1)	(95)	(107)		
Profit before tax ³	450	32	418	414	1%	
Earnings per share ³			35.5	33.9	5%	
Total dividend per share			15.2p	14.4p	6%	
Free cash flow			219	274		

1. Continuing operations exclude Personal Care which is classified as a discontinued operation.

2. Continuing operations exclude Personal Care and Closures which are classified as discontinued operations.

3. Underlying measures exclude exceptional items, amortisation of certain intangible assets, and fair value changes on certain operating and financing derivatives.

4. Organic change is at constant currency.

Beverage Cans – overall volume up 6%

- **Europe – growth in a challenging macro environment**
 - Market up 4%, Rexam overall volume up 3%
 - Standard cans (ex Russia) up 1%: despite tougher macro environment, a focus on returns and Spanish VAT increase
 - Specialty cans (ex Russia) up 6%: driven by energy drinks
 - Russia up 4%: stronger H2 due to good growth in beer despite changing regulatory environment

- **North America – share recovery continued**
 - Market flat, Rexam overall volume up 12%
 - Standard can volume up 10% as we recovered c.1/3rd of the volume lost in 2011
 - Specialty cans up 18% - driven by growth in Sleek, 16oz and 24oz for beer, iced teas and energy drinks

- **South America – improved H2**
 - Market¹ up 7%, Rexam overall volume up 5%
 - Standard cans up 4% continued growth in beer and csd
 - Specialty cans up 8% primarily driven by beer




Beverage Cans – operating profit¹ up 5%

- **Sales**
 - Volume up 6%
 - Pass through of lower aluminium costs
- **Volume/mix**
 - Share recovery in North America
 - Good growth in Europe and South America
- **Efficiencies**
 - Lightweighting of cans and ends
 - Lower energy consumption
- **Price/ costs**
 - Higher conversion costs in Europe
 - Higher premium costs in Europe and South America
 - Pricing in all regions offset other cost inflation
- **2013 costs**
 - Metal: premium and conversion cost flow through from 2012
 - Labour costs: LTIP and other
 - IAS 19: allocation of £7m in administration costs

Continuing operations

£m	2012	2011	Rep chg	Org chg ¹
Sales	3,885	3,786	3%	4%
Op profit ²	456	447	2%	5%
ROS	11.7%	11.8%		
RONA	32.7%	31.6%		

Beverage Cans
Organic change in operating profit^{1,2}



1. Organic change is at constant currency.

2. Underlying operating profit excludes exceptional and other items.


Healthcare – specific challenges

- **Healthcare sales down 2%¹**
 - Pharma: Strong growth of insulin pens and multi layer containers offset by impact of key product coming off patent and loss of animal health product
 - Prescription: Good pricing despite lower volumes due to a weak flu season in Q1 2012
 - Primary Packaging: Increased competition and pricing pressures
- **Efficiencies**
 - Lean manufacturing and energy usage
- **Volume/ mix**
 - Good growth in Pharma offset by lower primary packaging volumes
- **Price**
 - Good pricing in Prescription more than offset by impact of key product coming off patent
- **Costs**
 - Higher labour costs
 - IAS 19: allocation of £1m in administration costs

Continuing operations

£m	2012	2011	Rep chg	Org chg ¹
Sales	427	446	(4)%	(2)%
Op profit ²	48	65	(26)%	(24)%
ROS	11.2%	14.6%		
RONA	26.0%	38.2%		

Healthcare
Organic change in operating profit^{1,2}



1. Organic change is at constant currency.

2. Underlying operating profit excludes exceptional and other items.

Income statement – continuing operations¹

- **Associates & JVs**
 - South Korea and Guatemala

- **Interest**
 - Average interest rate c.6% (2011: c.6%)
 - 2013 H1 expected to be c.6% due to the additional cost of pre-financing bonds maturing in March and June; FY charge expected to be c.5%

- **Retirement benefits net finance cost**
 - 2012 charge £14m
 - 2013 charge under the revised IAS 19 expected to be c.£16m (2012 restated: £19m)

- **Tax**
 - Tax rate of 26% (2011: 29%)
 - Expected to be 28% for 2013

£m	2012	2011
Beverage Cans	3,885	3,786
Healthcare	427	446
Total sales	4,312	4,232
Beverage Cans	456	447
Healthcare	48	65
Underlying operating profit	504	512
Associates & JVs	9	9
Net interest expense	(81)	(91)
Retirement benefit obligations net finance cost	(14)	(16)
Total net finance cost	(95)	(107)
Underlying PBT	418	414
Tax	(109)	(118)
Underlying profit after tax	309	296

Exceptional and other items

£m	Continuing	Discontinued (Personal Care)	Total 2012
Profit on disposal	-	125	125
Impairment of goodwill	-	(181)	(181)
Restructuring of businesses	(33)	(11)	(44)
Amortisation of intangible assets	(18)	(3)	(21)
Fair value changes on operating derivatives	7	-	7
Fair value changes on financing derivatives	(20)	-	(20)
Exceptional and other items	(64)	(70)	(134)
Tax	19	3	22
Total	(45)	(67)	(112)

- Personal Care sale: profit on disposal partly offsets impairment of goodwill
- Total restructuring costs £44m (including £8m non cash)
 - Cash cost £4m in 2012 and £11m in 2013
 - Cash cost in future years £21m

Cash flow

- **Working capital**
 - Working capital management offset impact of higher volumes

- **Capital expenditure**
 - Principally projects to support Beverage Can growth

- **Restructuring**
 - 2012 costs related to Closures and Personal Care disposals
 - 2011 costs related to Closures disposal and Beverage Can restructuring

£m	2012	2011
Underlying operating profit	504	512
Depreciation and amortisation	160	161
Change in working capital	(10)	(5)
Capital expenditure (net)	(258)	(191)
Net interest and tax paid	(144)	(144)
Restructuring costs	(10)	(16)
All other movements	(23)	(43)
FCF – continuing	219	274
FCF – discontinued	(26)	(29)
Free cash flow – total	193	245
Dividends	(128)	(111)
Disposals	409	204
Foreign exchange/other	57	34
Opening net borrowings	(1,312)	(1,684)
Closing net borrowings	(781)	(1,312)

Balance sheet

- **Net debt c.£0.8bn (2011: £1.3bn)**
 - Undrawn bank facilities of £800m
- **Refinanced 2013 maturities**
 - Savings of c.£20m p.a. from H2 2013
 - Next significant debt maturity in 2017

Timing £m	Borrowings	Cash, cash equivalents and other ³	Net debt
Dec 2012	(2,212)	1,431	(781)
Feb/ April 2013 - Return of cash	-	(395)	(395)
March 2013 – Repayment of bond	518	(518)	-
June 2013 – Repayment of bond	385	(385)	-
Dec 2012 Pro forma	(1,309)	133	(1,176)


- **Net debt/ EBITDA 1.8x¹ (2011: 1.9x)**
- **P&L interest cover 6.2x (2011: 5.6x)**
- **Credit Rating:**
 - Standard & Poor's BBB-/ Stable outlook
 - Moody's Baa3/ Stable outlook
- **Net retirement benefit liability £355m (2011: £371m)**
- **ROCE 14.7% (2011: 13.7%)**

1. Based on pro forma net debt of £1.2bn, including return of cash.


2. Gross drawn debt.

3. Other includes financing derivatives and pension escrow investments.


Interest profile²



Debt profile²



Currency profile²



Financial summary

- Increased profit despite headwinds
- Strong balance sheet
- Improved ROCE to 14.7%
- Continued focus on cash, cost and return on capital employed

REXAM

Graham Chipchase

Chief Executive

On track for ROCE target of 15% in 2013

- Asset utilisation
- Efficiencies
- Innovation
- Emerging markets
- Managing the portfolio

Capital investment – significant projects


Beverage Cans		Total project cost	Nameplate capacity	On stream
Line conversion Sleek, Chicago, United States	Specialty	£5m	-	Q4 2012
Line conversion, 24oz Pouso Alegre, Brazil	Specialty	£5m	-	Q4 2012
New line, Mumbai, India	Standard	£30m	0.8bn	Q4 2012
New plant, Mäntsälä, Finland (two lines)	Standard	£70m	1.4bn	Line 1 Q1 2013
New line, Ludesch, Austria	Specialty	£20m	0.7bn	Q3 2013
New plant, Belém, Brazil	Standard	£35m	0.8bn	Q1 2013
Line speed ups in Egypt, Chile, Brazil, US	Specialty and Standard	£45m	1bn	2013
New Fusion Contour Line, Ejpovice, Czech	Specialty	£35m	0.2bn	Q1 2015
New plant, Widnau, Switzerland (initially 3 lines)	Specialty	£115m	2.2bn	Line 1 2015
Healthcare		Total project cost	On stream	
Increase existing capacity, Bangalore, India		£5m	Q3 2013	
Expansion of insulin pen capacity, La Verpilliere, France		£15m	Q4 2013	
Industrialisation of Advancia, Le Treport, France		£10m	2015	

Efficiencies

- **Revised target £25m p.a.**
 - Reflects disposal of Personal Care

- **2012 Efficiency savings of £26m**
 - Beverage cans:
 - Downgauging and light weighting
 - Lower energy usage

 - Healthcare:
 - Lower scrap
 - Increased labour productivity



Innovation



Multi label
technology
Brazil



Fusion
Countour™



12oz Sleek™
North
America



Safe'n'Sound™
and
Advancia™

Emerging markets: 34% of Group¹ sales



On track for ROCE target of 15% in 2013

- Asset utilisation
- Efficiencies
- Innovation
- Emerging markets
- Managing the portfolio

Our journey from 2009 to 2012

	2009 - 2012
Balance sheet strengthened	Net debt/EBITDA from 2.7x to 1.8x ¹
Free cash flow generated	c.£750m
Restructuring and efficiency savings	c.£150m
Operating profit ² improved	From £383m to £504m
Cash returned to shareholders (Dividends ³ + B share scheme)	£820m
Portfolio focused: sale of Closures and Personal Care	c.£600m in proceeds
ROCE improved	From 9.5% to 14.7%


On track for 15% ROCE in 2013

1. Based on pro forma net debt of £1.2bn.

2. Continuing operations.

3. Includes 2012 proposed final dividend of 10.2p per share.


Focused on creating shareholder value



Capital allocation beyond 2013

Cash generation

- Free cash flow
 - c£200m p.a.
- Strong balance sheet
 - 1.8x net debt/ EBITDA with a 2.0-2.5x target
- Portfolio management



Uses of cash

- Organic investment
 - Existing and new geographies
- M&A
 - Bolt-ons
 - Consolidation
- Increased dividend pay-out
- Surplus cash

Cash returns to shareholders

Maximise long term shareholder value and driving growth through disciplined capital allocation, while maintaining ROCE at c.15%

Progress in 2012 and outlook for 2013

- **GDP+ growth**
- **Continued to deliver on 3Cs**
- **Recovering volume in North America**
- **Disposal of Personal Care and Return of Cash**
- **Dividend growth**



We expect to make further progress in 2013 despite an uncertain macroeconomic environment and continued cost pressures. Further contractual gains in North America, and continued growth in our European and South American businesses give us confidence we will achieve our 15% ROCE target

REXAM

Q & A

REXAM

Appendix

Retirement benefit liability

- **UK – deficit marginally higher**
 - Reduction in discount rates partially offset by better than anticipated asset performance and cash contributions
- **US – deficit down slightly**
 - Better than anticipated asset performance and cash contributions offsets reduction in discount rates
- **2012**
 - Service charge continuing operations £25m
 - Cash outflow c.£70m (including deficit cash contributions of \$50m in US and £5m in UK)
- **2013 and IAS 19 revised**
 - Service charge continuing operations c.£36m (2012 restated: £33m)
 - Net finance retirement benefit charge c.£16m (2012 restated: £19m)
 - Cash outflow c.£65m (including deficit cash contributions of \$50m in US)
 - Deficit calculation unaffected by IAS 19 revised
- **Sensitivities of gross liability**
 - 10% +/- equities £100m
 - 0.5% +/- discount rate £70m

£m	As at 31.12.12	As at 31.12.11
UK defined benefit pensions	(20)	(13)
US defined benefit pensions	(323)	(350)
Other pensions	(66)	(63)
US retiree medical	(107)	(114)
Gross liability	(516)	(540)
Tax	161	169
Net liability	(355)	(371)

Foreign exchange translation¹

£m	Sales	Operating profit ²
Euro	(70)	(13)
US dollar	15	2
Russian rouble	(13)	(3)
Other currencies	(9)	-
Total	(77)	(14)

- Average:
 - Euro/£1.23 (2011: 1.15)
 - US\$/£1.59 (2011: 1.60)
 - Rouble/£49.24 (2011: 47.12)

1. Continuing operations.

2. Underlying excluding exceptional and other items.

December 2012 ROCE calculation

£m	Dec 2011	Dec 2012	2012
Underlying operating profit:			
Continuing operations			504
Discontinued operations			33
Associates/JVs			<u>9</u>
Underlying profit			<u>546</u>
Shareholders' equity	2,319	2,287	
Add back:			
Net borrowings	1,312	781	
Retirement benefits (net after tax)	<u>371</u>	<u>355</u>	
Capital employed	<u>4,002</u>	<u>3,423</u>	
Average capital employed	<u>3,713</u>		
ROCE (Underlying profit/Average capital employed)			<u>14.7%</u>

Net debt/EBITDA ratios

Leverage ratios £m		2012	2012 Pro forma ²
Reported basis	Net debt	781	1,176
	EBITDA ¹	664	664
	Reported net debt/EBITDA	1.2x	1.8x
Covenant basis	Net debt	781	
	50% of hybrid bond	(313)	
	Impact of average FX rates on debt	17	
	Adjusted net debt	485	
	Covenant net debt/EBITDA	0.7x	

1. Underlying continuing operations.

2. Including return of cash of £395m in H1 2013.

Debt facility profile

	Currency ¹	£m	Expiry
<u>Subordinated bond</u>			
EUR 750m	USD/ EUR	625	June 2067
<u>Bonds</u>			
USD 175	USD	108	Dec 2024
USD 395 ²	USD	337	Dec 2022
EUR 25	EUR	20	Dec 2022
USD 775m ²	USD	385	June 2013
EUR 637.5m	EUR	518	March 2013
<u>Bank facilities</u>			
Bilaterals	GBP	809	Nov 2017 ³
Principal committed facilities		2,802	

- Exchange rates at 31 December 2012: GBP/ USD 1.62 and GBP/Euro 1.23

1. Denominated in swapped currency where appropriate.

2. Reflects \$150m (£93m) draw down of a new and part repayment of an existing US private placement in January 2013.

3. Option to extend to 2018.